Advances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles

ACS Nano. 2023 Mar 28;17(6):5187-5210. doi: 10.1021/acsnano.2c11965. Epub 2023 Mar 10.

Abstract

Red blood cells (RBCs) and RBC membrane-derived nanoparticles have been historically developed as bioinspired drug delivery systems to combat the issues of premature clearance, toxicity, and immunogenicity of synthetic nanocarriers. RBC-based delivery systems possess characteristics including biocompatibility, biodegradability, and long circulation time, which make them suited for systemic administration. Therefore, they have been employed in designing optimal drug formulations in various preclinical models and clinical trials to treat a wide range of diseases. In this review, we provide an overview of the biology, synthesis, and characterization of drug delivery systems based on RBCs and their membrane including whole RBCs, RBC membrane-camouflaged nanoparticles, RBC-derived extracellular vesicles, and RBC hitchhiking. We also highlight conventional and latest engineering strategies, along with various therapeutic modalities, for enhanced precision and effectiveness of drug delivery. Additionally, we focus on the current state of RBC-based therapeutic applications and their clinical translation as drug carriers, as well as discussing opportunities and challenges associated with these systems.

Keywords: cell membrane; drug delivery; extracellular vesicles; hitchhiking; nanoparticles; pharmacokinetics; red blood cells; therapeutics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Drug Carriers
  • Drug Delivery Systems*
  • Erythrocytes
  • Nanoparticles* / therapeutic use

Substances

  • Drug Carriers